title: Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
authors: University of California, San Francisco, San Francisco, CA.
authors: Robin K
authors: RK
authors: Kelley
mesh_terms: D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010166:Palliative Care; D010671:Phenylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D016879:Salvage Therapy; D000077157:Sorafenib; D014227:Triazines / Q000627:therapeutic use*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D014227:Triazines; D009536:Niacinamide; D000077157:Sorafenib; C509922:brivanib; D000409:Alanine